BBIO stock forecast aligns with macroeconomic indicators favoring biotech growth. Federal funding programs for genetic research could indirectly boost commercialization prospects. BridgeBio has caught the attention of Oppenheimer analyst Trevor Allred, who is taking a more bullish stance on the shares in light of Attruby’s successful commercialization. Allred writes, “We’ve been wrong on BBIO since our initiation—Bridgebio’s team has executed Attruby’s launch superbly, and shares have been supported by commercial outperformance and a look-ahead to clinical catalysts at YE. Our trepidation around 2029 generic entry has not mattered for 2025 stock performance. We expect share outperformance to continue as 2025 Attruby sales clear consensus estimates, and we expect commercial success to be compounded by positive clinical results from ADH1 and LGMD2i clinical trials around YE. Our concerns regarding long-term revenue durability remain, but BBIO has time to demonstrate real-world datasets demonstrating benefit over tafamidis should generics become available in 2029.” Multiple analysts have issued price targets for $BBIO recently. We have seen 14 analysts offer price targets for $BBIO in the last 6 months, with a median target of $66.5. BBIO stock forecast incorporates the company’s recent breakthrough in gene therapy, which could be a revenue catalyst. Year-over-year R&D expenditure increased by 18%, a signal of pipeline expansion positioning.
